Cargando…

A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations

PURPOSE: To determine the safety and efficacy of PARP plus PD-L1 inhibition (olaparib + durvalumab, O + D) in patients with advanced solid, predominantly rare cancers harbouring homologous recombination repair (HRR) defects. PATIENTS AND METHODS: In total, 48 patients were treated with O + D, 16 wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thavaneswaran, Subotheni, Kansara, Maya, Lin, Frank, Espinoza, David, Grady, John P., Lee, Chee Khoon, Ballinger, Mandy L., Sebastian, Lucille, Corpuz, Theresa, Qiu, Min Ru, Mundra, Piyushkumar, Bailey, Charles G., Schmitz, Ulf, Simes, John, Joshua, Anthony M., Thomas, David M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403555/ https://www.ncbi.nlm.nih.gov/pubmed/37365284 http://dx.doi.org/10.1038/s41416-023-02311-0

Ejemplares similares

Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology
por: Lin, Frank P., et al.
Publicado: (2021)

Early circulating tumor DNA dynamics as a pan‐tumor biomarker for long‐term clinical outcome in patients treated with durvalumab and tremelimumab
por: Kansara, Maya, et al.
Publicado: (2022)

The experiences and needs of Australian medical oncologists in integrating comprehensive genomic profiling into clinical care: a nation-wide survey
por: Thavaneswaran, Subotheni, et al.
Publicado: (2021)

Clinical Response to Seribantumab, an Anti–Human Epidermal Growth Factor Receptor-3 Immunoglobulin 2 Monoclonal Antibody, in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma Harboring an NRG1 Fusion
por: Thavaneswaran, Subotheni, et al.
Publicado: (2022)

Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment
por: Fumet, Jean-David, et al.
Publicado: (2020)

Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer
por: Moutafi, Myrto, et al.
Publicado: (2023)

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
por: Karzai, Fatima, et al.
Publicado: (2018)

Stability of building gene regulatory networks with sparse autoregressive models
por: Rajapakse, Jagath C, et al.
Publicado: (2011)

Sunglasses to hide behind may also prevent melanoma of the eyes
por: Dhomen, Nathalie, et al.
Publicado: (2021)

Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair protein
por: Ghiringhelli, Francois, et al.
Publicado: (2016)

Extrapolating evidence for molecularly targeted therapies from common to rare cancers: a scoping review of methodological guidance
por: Cho, Doah, et al.
Publicado: (2022)

Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU)
por: Rosenberg, Jonathan E., et al.
Publicado: (2023)

When do patient reported quality of life indicators become prognostic in breast cancer?
por: Lee, Chee Khoon, et al.
Publicado: (2018)

Olaparib in the management of ovarian cancer
por: Bixel, Kristin, et al.
Publicado: (2015)

Normalized LST Is an Efficient Biomarker for Homologous Recombination Deficiency and Olaparib Response in Ovarian Carcinoma
por: Christinat, Yann, et al.
Publicado: (2023)

Olaparib-Induced Immune-Mediated Liver Injury
por: Alshelleh, Mohammad, et al.
Publicado: (2022)

PIKE-R2P: Protein–protein interaction network-based knowledge embedding with graph neural network for single-cell RNA to protein prediction
por: Dai, Xinnan, et al.
Publicado: (2021)

Functional classification of DDOST variants of uncertain clinical significance in congenital disorders of glycosylation
por: Kas, Sjors M., et al.
Publicado: (2023)

Next-generation sequencing, should I use anti-HER2 therapy for HER2-amplified tumors off-label? Illustrating an extrapolation framework
por: Cho, Doah, et al.
Publicado: (2022)

Highly sensitive inference of time-delayed gene regulation by network deconvolution
por: Chen, Haifen, et al.
Publicado: (2014)

Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model
por: Borst, Gerben R., et al.
Publicado: (2017)

Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells
por: Mani, Chinnadurai, et al.
Publicado: (2019)

Panobinostat enhances olaparib efficacy by modifying expression of homologous recombination repair and immune transcripts in ovarian cancer
por: Wilson, Andrew J., et al.
Publicado: (2021)

Olaparib in patients with mCRPC with homologous recombination repair gene alterations: PROfound Asian subset analysis
por: Matsubara, Nobuaki, et al.
Publicado: (2022)

Transient Response of Olaparib on Pulmonary Artery Sarcoma Harboring Multiple Homologous Recombinant Repair Gene Alterations
por: Wu, Chiao-En, et al.
Publicado: (2021)

Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance
por: Wang, Li‐Min, et al.
Publicado: (2023)

Durvalumab activity in previously treated patients who stopped durvalumab without disease progression
por: Sheth, Siddharth, et al.
Publicado: (2020)

TIPS-21 PHASE I/II STUDY OF STEREOTACTIC RADIOSURGERY WITH CONCURRENT OLAPARIB FOLLOWED BY ADJUVANT DURVALUMAB AND PHYSICIAN’S CHOICE SYSTEMIC THERAPY IN SUBJECTS WITH BREAST CANCER BRAIN METASTASES (SOLARA)
por: Shen, Colette, et al.
Publicado: (2023)

Durvalumab-associated generalized morphea with overlapping vitiligo
por: Martel, Julianna, et al.
Publicado: (2022)

Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis
por: Sjoquist, Katrin M., et al.
Publicado: (2018)

Durvalumab: First Global Approval
por: Syed, Yahiya Y.
Publicado: (2017)

Retinal Vasculitis Secondary to Durvalumab
por: R. Andrade, Antonio, et al.
Publicado: (2020)

Durvalumab-induced Severe Gastritis
por: Otohara, Masaya, et al.
Publicado: (2021)

Correction: Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model
por: Borst, Gerben R., et al.
Publicado: (2020)

Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma
por: Alt, Marie, et al.
Publicado: (2023)

A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses
por: Zimmer, Alexandra S., et al.
Publicado: (2019)

Olaparib in Epithelial Ovarian Cancer
por: Anastasia, Paula J.
Publicado: (2016)

Olaparib: Transcending mutational barriers
por: Chandna, Abhishek
Publicado: (2019)

Olaparib and somatic BRCA mutations
por: George, Angela, et al.
Publicado: (2017)

Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro
por: Borchert, Sabrina, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_4qmkjubl4nosu832l11ja90s5o